Current problems in hypertension and nephrology

Expert Opinion on Pharmacotherapy

Volumn 11, Issue 16, 2010, Pages 2575-2578

  Banach, MacIej ^a   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Chronic kidney disease; Current problems; Hypertension

Indexed keywords

ALDOSTERONE ANTAGONIST; ALDOSTERONE RECEPTOR; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NEBIVOLOL; RENIN INHIBITOR;

ACUTE CORONARY SYNDROME; ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFICACY; DYSLIPIDEMIA; HEART INFARCTION; HUMAN; HYPERTENSION; MONOTHERAPY; MORTALITY; NEPHROLOGY; PROTEINURIA; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SODIUM INTAKE; SODIUM RESTRICTION; STROKE; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; CHRONIC DISEASE; DYSLIPIDEMIAS; HUMANS; HYPERTENSION; KIDNEY DISEASES;

EID: 78049398580     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2010.522569     Document Type: Review

References (30)

1. Mancia G, Laurent S, Agabiti-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009;27:2121-58
2. Banach M, Kjeldsen SE, Narkiewicz K. Editorial. Controversies in hypertension treatment. Curr Vasc Pharmacol 2010;731-2
3. Gaciong Z, Symonides B. Hypertension 2010: what was new for the cardiologist? Expert Opin Pharmacother 2010; In press
4. Banach M, Barylski M, Rysz J. What should be the optimal levels of blood pressure? J-curve phenomenon. The scene after ACCORD BP publication. Evid Based Cardiol 2010;1:113-20
5. Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE. The J-curve phenomenon revisited. Blood Press 2009;18:168-70
6. Desai RV, Banach M, Ahmed MI, et al. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol 2010;106:221-7
7. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. Current place of beta-blockers in the treatment of hypertension. Curr Vasc Pharmacol 2010;733-41
8. Ramezani MA, Dastanpour M, Eshaghi SR, et al. Determinants of awareness, treatment and control of hypertension in Isfahan, Central Iran. Arch Med Sci 2009;5:523-30
9. Ruilope LM, Segura J. ARBs and ACEIs together in the treatment of hypertension and its complications? Current practical recommendations. Expert Opin Pharmacother 2010; In press
10. Gustafsson F, Segura J, Ruilope LM. How should we manage heart failure developing in patients already treated with ACE inhibitors and beta-blockers for hypertension, diabetes or coronary disease. J Hypertension 2010;28:1595-8
11. Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010; In press
12. Tatli E, Aktoz M, Gul C, et al. Does carvedilol therapy reduce QT dispersion in patients with heart failure? Arch Med Sci 2008;4:404-8
13. Gasowski J, Tikhonoff V, Stolarz-Skrzypek K, et al. Treatment of hypertension in the elderly in 2010-a brief review. Expert Opin Pharmacother 2010; In press
14. Beckett NS, Peters R, Fletcher AE, et al.; HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98
15. Aronow WS. Why and how we should treat elderly patients with hypertension? Curr Vasc Pharmacol 2010;780-7
16. Jissho S, Shimada K, Taguchi H, et al. Impact of electrocardiographic left ventricular hypertrophy on the occurrence of cardiovascular events in elderly hypertensive patients. The Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Circ J 2010;74:938-45
17. Kostapanos MS, Milionis HJ, Elisaf MS. Current role of statins in the treatment of essential hypertension. Expert Opin Pharmacother 2010; In press
18. Gluba A, Rysz J, Banach M. Statins in patients with chronic kidney disease. Why, whom and when? Expert Opin Pharmacother 2010; In press
19. Banach M, Mikhailidis DP, Kjeldsen SE, Rysz J. Time for new indications for statins? Med Sci Monit 2009;15:MS1-5
20. Stepien M, Banach M, Mikhailidis DP, et al. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009;25:1995-2005
21. Rysz J, Aronow WS, Stolarek RS, et al. Nephroprotective and clinical potential of statins in dialyzed patients. Expert Opin Ther Targets 2009;13:541-50
22. Cravedi P, Ruggenenti P, Remuzzi G. Which antihypertensive drugs are the most nephroprotective and why? Expert Opin Pharmacother 2010; In press
23. Stepien M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol 2010;747-52
24. Ruggenenti P, Cravedi P, Remuzzi G. Proteinuria: increased angiotensin-receptor blocking is not the first option. Nat Rev Nephrol 2009;5:367-8
25. Goch A, Banach M, Mikhailidis DP, et al. Endothelial dysfunction in patients with noncomplicated and complicated hypertension. Clin Exp Hypertens 2009;31:20-30
26. Hart PD, Bakris GL. Hypertensive nephropathy: prevention and treatment recommendations. Expert Opin Pharmacother 2010; In press
27. Safar ME, Jankowski P. Destiffening procedure and antihypertensive therapy. Expert Opin Pharmacother 2010; In press
28. Rodriguez-Iturbe B, Correa-Rotter R Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert Opin Pharmacother 2010; In press
29. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci 2009;5:3-9
30. Moynihan R Who benefits from treating prehypertension? BMJ 2010;341:c4442